LENEXA, Kan., May 7, 2025 -- Eurofins Viracor, a leading specialty diagnostics laboratory, is proud to announce a groundbreaking advancement in respiratory infection diagnostics with the launch of a new bronchoalveolar lavage (BAL) specimen type for its NeXGen® Fungal / Acid Fast Bacteria Next Generation Sequencing (NGS) assay.
Eurofins Viracor launches BAL specimen testing for NeXGen Fungal/AFB NGS assay.
Traditional methods for diagnosing these infections, such as cultures, are often time-consuming and may miss atypical or slow-growing species. The NeXGen® Fungal / AFB NGS assay overcomes these limitations by utilizing the power of Next Generation Sequencing to analyze DNA, enabling precise identification of over 600 fungal and AFB species directly from BAL samples.
Key benefits of the NeXGen® Fungal / AFB NGS assay with BAL specimens include:
- Identification of a wide range of fungal and AFB pathogens, including rare or atypical species.
- Significantly faster turnaround time compared to traditional cultures for these slow growing and difficult to identify pathogens.
- Potential for earlier initiation of appropriate therapy, reducing morbidity and mortality.
Eurofins Viracor's commitment to innovation in infectious disease diagnostics is exemplified by this advancement.
For more information about the NeXGen® Fungal / AFB NGS assay and its application with BAL specimens, please visit https://www.eurofins-viracor.com/test-menu/33356-nexgen-fungal-afb-next-generation-sequencing-ngs-assay/ or contact Client Services at (800) 305-5198.
About Eurofins Viracor
With over 40 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Eurofins Viracor is passionate about delivering accurate, timely and actionable results, never losing sight of the connection between the testing it performs and the patients it serves.
Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit eurofins.com and eurofins-viracor.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralized and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies' broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.
Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
